CClinicalTrials.gg
RecruitingNCT05578196Updated May 17, 2024

Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.

An interventional study of fecal bacteria solution and physiological saline solution in Sepsis and Infections, sponsored by Shanghai 10th People's Hospital. Recruiting at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2024-05-17.

Sponsored by Shanghai 10th People's Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
14 Years and older
Sex
All
01

Study summary

Fecal microbial transplantation is to transplant functional microbiota from the feces of healthy people into the gastrointestinal tract of patients, reconstruct new intestinal microbiota, and realize the treatment of intestinal and extra-intestinal diseases. Compared with ordinary commercial probiotics, FMT is more consistent with the composition of the intestinal microecological structure and can recover intestinal flora to the maximum extent and faster. FMT increases intestinal bacteria production function and helps to restore the systemic immune response so that sepsis pathogens are removed. The aim of this trial was to investigate the clinical effect of FMT in the treatment of patients with severe infections.

Read the detailed description

The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.

02

Conditions studied

  • Sepsis
  • Infections
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's planned enrollment of 110 is close to the median of 120 across 4,200 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Shanghai 10th People's Hospital is the lead sponsor of 167 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients diagnosed with severe infections, which is infected patients SAFA≥2 OR APACHE Ⅱ≥15
  • Aged ≥14 years
  • Patients or their family members agreed to participate in this study

Exclusion criteria

Exclusion Criteria:

  • Advanced tumors or diseases associated with systemic immunosuppression
  • Pregnant women
  • Patients with severe intestinal ulcer or perforation
  • Unable to complete oral administration and no effective artificial feeding pipeline.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    The experimental group with FMT

    The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group

    Drug: fecal bacteria solution

  • Other
    The control group with physiological saline

    The gastrointestinal tube access was established, and the standard preparation of physiological saline solution 20ml

    Drug: physiological saline solution

Interventions

  • Drugfecal bacteria solution

    The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.

  • Drugphysiological saline solution

    physiological saline solution 20ml

06

What researchers measure

Primary outcomes

  1. Death

    Clinical outcome

    Time frame: up to 28 days in ICU

Secondary outcomes

  1. Gut microbiota distribution assessed by 16SrDNA

    16SrDNA

    Time frame: up to 6 days after fecal microbial transplantation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Haak BW, Prescott HC, Wiersinga WJ. Therapeutic Potential of the Gut Microbiota in the Prevention and Treatment of Sepsis. Front Immunol. 2018 Sep 10;9:2042. doi: 10.3389/fimmu.2018.02042. eCollection 2018. PubMed 30250472 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05578196
Lead sponsor
Shanghai 10th People's Hospital
Responsible party
Chen Yuanzhuo (associate chief physician, Shanghai 10th People's Hospital) — Principal investigator
First posted
Oct 13, 2022
Start date
Sep 4, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
May 17, 2024

Study contacts

YuanZhuo Chen
Contact
chenyuanzhuo@tongji.edu.cn
13764528213
YuanZhuo Chen
study chair · Shanghai 10th People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion